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Identity 
Other names: VRL, VRL-1, VRL1 
HGNC (Hugo): TRPV2 
Location: 17p11.2 
Local order:  
Colocolizes upstream with UBB (ubiquitin B) and 
FTLP12 (ferritin, light polypeptide pseudogene 12), 
and downstream with C17orf76-AS1 (C17orf76 
antisense RNA 1) (non-protein coding). 
DNA/RNA 
Description 
TRPV2 gene consists of 15 exons and 14 introns 
spanning 1 to 21462 bp of DNA from 17p11.2 and 
includes a 5'-/3'- non-coding regions. The position of 
exons is: 1-292, 2021-2327, 4574-4707, 7058-7348, 
7928-8226, 10558-10728, 11181-11336, 11908-12006, 
12776-12846, 13276-13441, 16243-16309, 16425-
16759, 18033-18157, 19349-19428, 21248-21462. 
 
 
Schematic representation of human TRPV2 gene and neighbouring genes. UBB: ubiquitin B; FTLP12: ferritin, light polypeptide 
pseudogene 12; C17orf76-AS1: C17orf76 antisense RNA 1 non-protein coding. 
 
Genomic structure of human TRPV2 gene. The coding region is shown with red colour. The non-translated regions are shown with black 
colour. 
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The canonical form comprises 764 aa (MW ~86 kDa) and is composed of six transmembrane spanning domains and a pore forming 
region between transmembrane domains 5 and 6. The N-terminal and C-terminal tails are in cytoplasmatic side. Six N-terminal ankyrin 
(ANK) repeats are present in N-terminal tail. 
 
Transcription 
mRNA product length 2829 bp. No alternative splice 
variants have been found so far. 
Protein 
Note 
A transmembrane protein of vanilloid family, member 
2, TRPV2 channel. 
Description 
It is a glycosylated membrane protein (764 aa, MW 
~86 kDa) with 6 transmembrane regions and a pore-
forming loop. N- and C-terminal tails are in 
cytoplasmic side. TRPV2 contains 6 ankyrin repeats 
may play a role in the interaction between subunits and 
is probably homotetramer. Interacts with a cAMP-
dependent protein kinase type II regulatory subunit 
(PRKAR2A or PRKAR2B) and ACBD3. Interacts with 
SLC50A1; the interaction probably occurs 
intracellularly and depends on TRPV2 N-glycosylation. 
This protein forms a non-selective cationic channel i  
the plasma membrane and is activated by temperatures 
higher than 52 degrees Celsius; and is not activated by 
vanilloids and acidic pH. 
Expression 
TRPV2 channel is expressed in the advanced stages of 
prostate cancer. TRPV2 transcript levels are higher in 
patients with metastatic cancer (stage M1) compared 
with primary solid tumors (stages T2a and T2b). 
TRPV2 channel is expressed in PC3 and DU-145 cell 
lines derived from bone and brain metastasis, 
respectively (Monet et al., 2009; Monet et al., 2010). 
TRPV2 protein is expressed in human hepatoblastoma 
(HepG2) cells (Vriens et al., 2004). TRPV2 was found 
to be more expressed at both the mRNA and protein 
levels in cirrhotic livers compared with chronic 
hepatitis, whereas it also occurred in moderately and
well-differentiated tumors compared with that of poorly 
differentiated tumors (Liu et al., 2010). In 
hepatocellular carcinoma the increased expression of 
TRPV2 was identified in 16/55 (29%) cases. The 
enhanced TRPV2 mRNA and protein expression was 
also found in high-grade and -stage urothelial 
carcinoma specimens and urothelial carcinoma cell 
lines. Both the full-length TRPV2 (hTRPV2) and a 
short splice-variant (s-TRPV2) were detected in normal 
human urothelial cells and normal bladder specimens, 
whereas a progressive decline of s-TRPV2 in pTa, pT1
and pT2 stages was observed, up to a complete loss in 
pT3 and pT4 urothelial carcinoma specimens 
(Caprodossi et al., 2008). TRPV2 mRNA was 
abundantly expressed in T24 cells as well (a poorly 
differentiated urothelial carcinoma cell line). TRPV2 is 
also expressed in the rat dorsal root ganglia and in F-11 
cells, a hybridoma derived from rat dorsal root gangli  
and mouse neuroblastoma (Yamada et al., 2010). 
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TRPV2 is expressed in the human larynx, which may 
act as laryngeal nociceptors perceiving luminal noxious 
stimuli. TRPV2 mRNA and protein are expressed in 
benign astrocyte tissues, and its expression 
progressively declined in high-grade glioma tissues as 
histological grade increased (n = 49 cases), and in 
U87MG cells and in MZC, FCL and FSL primary 
glioma cells (Nabissi et al., 2010). 
Localisation 
The biotinylation studies as well as calcium imaging 
experiments in some works suggest its expression on 
the plasma membrane (Monet et al., 2009; Monet et al., 
2010). It translocates from the cytoplasm to the plasma 
membrane upon ligand stimulation. 
Function 
TRPV2 is a calcium-permeable, non-selective cation 
channel with an outward rectification. Seems to be 
regulated, at least in part, by IGF-I, PDGF and 
neuropeptide head activator. May transduce physical 
stimuli in mast cells. Activated by temperatures higher 
than 52 degrees Celsius; is not activated by vanilloids 
and acidic pH. 
Homology 




An experimental mutation published in the C-
Terminus. In this study the authors identified a 
calmodulin binding site on the C-termini of TRPV2 
(654-683). The R679 and K681 single mutants of 
TRPV2 caused a 50% decrease in binding affinity and 
a double mutation of K661/K664 of the same peptide 
lowered the binding affinity by up to 75% (Holakovska 




TRPV2 protein is expressed in human hepatoblastoma 
(HepG2) cells and human hepatocellular carcinoma 
(Vriens et al., 2004). 
Prognosis 
Quantitative RT-PCR and Western blotting analysis 
revealed that expression of TRPV2 at both the mRNA 
and protein levels were increased in cirrhotic livers 
compared with chronic hepatitis, whereas that also 
occurred in moderately and well-differentiated tumors 
compared with that of poorly differentiated tumors (Liu 
et al., 2010). Immunohistochemistry of the 55 human 
hepatocellular carcinoma samples showed that the 
expression of TRPV2 increased when going from 
normal liver or chronic hepatitis to cirrhosis. Increased 
TRPV2 expression was observed in tissues of liver 
cirrhosis (31/37, 83,8%). In HCC, increased expression 
of TRPV2 was identified in 16/55 (29%) cases. 
Clinicopathologic assessment suggested a significant 
association between TRPV2 expression and portal vein 
invasion and histopathologic differentiation (P = 0,036 
and 0,001, respectively). The data suggest that TRPV2 
plays a role in human hepatocarcinogenesis and might 
be a prognostic marker of patients with human 
hepatocellular carcinoma. 
Oncogenesis 
Heat induces calcium entry into HepG2 cells. 
Bladder cancer 
Disease 
TRPV2 channel is expressed in urothelial carcinoma 
and TRPV2 mRNA is abundantly expressed in T24 
cells (a poorly differentiated urothelial carcinoma cell 
line) (Yamada et al., 2010). 
Prognosis 
Enhanced TRPV2 mRNA and protein expression was 
found in high-grade and -stage UC specimens and UC 
cell lines. Both the full-length TRPV2 (hTRPV2) and a 
short splice-variant (s-TRPV2) were detected in NHUC 
and normal bladder specimens, whereas a progressive 
decline of s-TRPV2 in pTa, pT1, and pT2 stages was 
observed, up to a complete loss in pT3 and pT4 UC 
specimens (Caprodossi et al., 2008). 
Oncogenesis 
The expression level in UC cells is correlated with 
high-grade disease. The administration of CBD 
increased intracellular calcium concentrations in T24 
cells. In addition, the viability of T24 cells 
progressively decreases with increasing concentrations 
of CBD, whereas RT4 cells are mostly unaffected. Cell
death occurs via apoptosis caused by continuous influx 
of calcium through TRPV2. 
Glia cancer 
Disease 
TRPV2 channel is expressed in glioma cells: U87MG, 
MZC, FCL and FSL primary human glioma cells 
(Nabissi et al., 2010). 
Prognosis 
The findings indicate that TRPV2 negatively controls 
glioma cell survival and proliferation. 
Oncogenesis 
TRPV2 silencing increases U87MG cell proliferation 
as shown by the increased percentage of cells 
incorporating 5-bromo-2-deoxyuridine expressing 
beta(III)-tubulin and rescued glioma cells to Fas-
induced apoptosis. In addition, transfection of TRPV2 
in MZC glioma cells, by inducing Fas overexpression, 
resulted in a reduced viability and an increased 
spontaneous and Fas-induced apoptosis. These findings 
indicate that TRPV2 negatively controls glioma cell 
survival and proliferation, as well as resistance to Fas-
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induced apoptotic cell death in an ERK-dependent 
manner (Nabissi et al., 2010). 
Prostate cancer 
Disease 
TRPV2 channel is expressed in the advanced stages of 
prostate cancer. TRPV2 transcript levels are higher in 
patients with metastatic cancer (stage M1) compared 
with primary solid tumors (stages T2a and T2b). 
TRPV2 channel is expressed in PC3 and DU-145 cell 
lines derived from bone and brain metastasis, 
respectively (Monet et al., 2009; Monet et al., 2010). 
Prognosis 
TRPV2 channel indicated that it is primarily involved 
in cancer cell migration and not in cell growth. A role 
for TRPV2 in prostate cancer progression to the 
aggressive castration-resistant stage has been 
suggested, prompting evaluation of TRPV2 as a 
potential prognostic marker and therapeutic target in 
the setting of advanced prostate cancer. 
Oncogenesis 
TRPV2 silencing decreases prostate cancer cell 
migration not affecting cell proliferation (Monet eal., 
2009). Introducing TRPV2 into androgen-dependent 
LNCaP cells enhanced cell migration along with 
expression of invasion markers matrix 
metalloproteinase (MMP) 9 and cathepsin B. Small 
interfering RNA-mediated silencing of TRPV2 reduced 
the growth and invasive properties of PC3 prostate 
tumors established in nude mice xenografts, and 
diminished expression of invasive enzymes MMP2, 
MMP9, and cathepsin B (Monet et al., 2010). 
Muscular dystrophy 
Note 
Mechanisms: TRPV2 is a principal Ca(2+)-entry route 
leading to a sustained [Ca(2+)](i) increase and muscle 
degeneration (Zanou et al., 2009). 
Disease 
When transgenic mice expressing a TRPV2 mutant in 
muscle are crossed with mdx mice, the [Ca(2+)](i) 
increase in muscle fibers is reduced by dominant-
negative inhibition of endogenous TRPV2 (Iwata et al., 
2009). 
Prognosis 
It was suggested a promising therapeutic target for he 
treatment of muscular dystrophy. 
Duchenne myopathy 
Note 
Mechanisms: a role of TRPV2 channel in the 
physiopathology of Duchenne muscular dystrophy has 
been suggested cause muscles from dystrophin-
deficient mice typically present an exaggerated 
susceptibility to eccentric work characterized by an 
important force drop and an increased membrane 
permeability consecutive to repeated lengthening 
contractions (Zanou et al., 2009). 
Disease 
Duchenne myopathy is a lethal disease due to the 
absence of dystrophin, a cytoskeletal protein (Zanou et 
al., 2009). 
Prognosis 
Muscles from dystrophin-deficient mice are largely 
protected from eccentric work-induced damage by 
overexpressing a dominant negative mutant of TRPV2 
ion channel. 
Norrbottnian congenital insensitivity to 
pain 
Note 
Mechanisms: a dramatic loss of such nerve fibers wa 
seen in skin from individuals with Norrbottnian 
congenital insensitivity to pain, further suggesting that 
these ion channels are expressed primarily on 
nociceptive primary sensory neurons in human skin 
(Axelsson et al., 2009). 
Disease 
Nerve fibers immunoreactive for TRPV2 are absent or 
substantially reduced in number in individuals with 
Norrbottnian congenital insensitivity to pain, an 
autosomal disease selectively affecting the 
development of C-fiber and Adelta-fiber primary 
afferents (Axelsson et al., 2009). 
Prognosis 
Nerve fibers in human skin express TRPV2 that co-
localizes with the sensory neuropeptides CGRP and SP, 
but not with NF200, VIP or TH. 
Hyperalgesia 
Note 
Mechanisms: upregulation of TRPV2 may play 
important roles in the mechanical hyperalgesia induce  
by cisplatin (Hori et al., 2010). 
Disease 
TRPV2 is expressed in sensory neurons and affects 
mechanical and thermal hyperalgesia examined in a rat
model of cisplatin-induced peripheral neuropathy 
(Kasama et al., 2007). 
To be noted 
Note 
TRPV2 knockout mice have been generated. 
Behavioral and electrophysiological responses to heat 
and mechanical stimuli were examined TRPV2 knock-
out mice (Park et al., 2011). TRPV2 knock-out mice 
showed reduced embryonic weight and perinatal 
viability. TRPV2 knock-out mice showed normal 
behavioral responses to noxious heat over a broad 
range of temperatures and normal responses to punctate 
mechanical stimuli, both in the basal state and under 
hyperalgesic conditions such as peripheral 
inflammation and L5 spinal nerve ligation. 
Electrophysiological recordings from skin afferents 
showed that C-fiber responses to heat and C- and Aδ-
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fiber responses to noxious mechanical stimuli were 
unimpaired in the absence of TRPV2. The prevalence 
of thermosensitive Aδ-fibers was too low to permit 
comparison between genotypes. Thus, TRPV2 is 
important for perinatal viability but is not essential for 
heat or mechanical nociception or hypersensitivity in 
the adult mouse (Park et al., 2011). 
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